The Inability To Provide For His Family, And Why It Drove Mr. Shimerda

The Inability to Provide for His Family, and Why it Drove Mr. Shimerda to Suicide My Antonia, by Willa Cather, is a novel about Jim Burden and his relationship and experiences growing up with Antonia Shimerda in Nebraska. Throughout the book Jim reflects on his memories of Nebraska and the Shimerda family, often times in a sad and depressing tone. One of the main ways Cather is able to provoke these sad emotions within the reader is through the suicide of Antonia's father, Mr. Shimerda. His death was unexpected by everyone and it is thought that homesickness is what drove him to take his own life. Homesickness was surely felt by Mr. Shimerda, as it was by many, but it was the failure to adequately find a way to provide for his family that sent Mr. Shimerda into a depressing downward spiral that left him no foreseeable alternative but to take his own life. The first descriptions of Mr. Shimerda are that of a successful businessman that had always provided well for his family. I noticed how white and well-shaped his own hands were. They looked calm, somehow, and skilled. His eyes were melancholy, and were set back deep under his brow. His face was ruggedly formed, but it looked like ashes - like something from which all the warmth and light had dried out. Everything about this old man was in keeping with his dignified manner (24) Mr. Shimerda was indeed a prosperous man in Bohemia, but had made his living in the business world, not by running a farm to provide for his family's needs. His hands show that he rarely performed hard manual labor, but that he did work hard with his hands to weave. His face however shows signs that he was already having doubts about the welfare of his family and their survival. The apparent glow that he must have once had was now replaced by the look of heavy thoughts. This came from the burden of providing for his family by way of very unfamiliar and difficult means. He had already lost a great deal of money in the family's traveling expenses and overpaid for their property. They paid way too much for the land and for the oxen, horses and cookstove (22). Mr. Shimerda must not have thought that he would have to support his family by means of plowing fields for food and actually building a home from materials gathered from the earth. He was a businessman and made a life for his famil y in Bohemia by working. He was a weaver by trade; had been a skilled work man on tapestries and upholstery materials (22). There was no work for him in this new country and he did not have the money to relocate his family. Certainly before he left Bohemia he believed that they had more than enough money to get by. The reality of his family's circumstances was just beginning to show their impact. Antonia points out to Jim that Mr. Shimerda looks ill My papa sick all the time Tony panted as we flew. He not look good, Jim (36). It is obvious that Mr. Shimerda was terribly stressed and was staring to show it physically. Most likely he looked ill due to not sleeping and eating. Nevertheless, Mr. Shimerda wanted desperately do the best that he could for his family. He moved his family with the hopes of finding good husbands for his daughters and wealth and land for his son. He calls onto Jim to teach Antonia to read. He does so in a very pleading, helpless way which leaves an unforgettab le memory in Jim's mind. Jim takes on the task, but unfortunately Mr. Shimerda gets little help from anyone else in the town for anything. Mr. Shimerda never really understands why he receives virtually little help from neighbors getting the farm going. He knows nothing about running the farm, and didn't even have the appropriate tools necessary. He and his family on the other hand are very trusting and would give the shirts off their backs to anyone who needed anything from them. There never were such a people as the Shimerdas for wanting to give away everything they had

Florida Tech University Online MBA Program Essays

Florida Tech University Online MBA Program Essays Florida Tech University Online MBA Program Essay Florida Tech University Online MBA Program Essay Florida Tech University  Online MBA Program has been educating prominent business executives, astronauts and decorated U.S. generals for over fifty years. With our internationally recognized team of  committed  faculty, a commitment to academic excellence and our alumni who keep the Florida Tech University tradition alive through our outstanding achievements. Earning a degree demands a significant time commitment on your part. You want to be absolutely sure that all your hard work will pay off with a degree that’s not only recognized but also respected.  Florida Tech University is nationally accredited.  Which  means you can be confident that the university has been judged  Ã‚  evaluated to consistently meet the high quality standards. Not only will potential employers recognize your degree from Florida Tech University, but many other regionally accredited institutions will recognize your credentials as well. Florida Tech University has perfected our video based E learning system with all the benefits of a traditional   on campus classroom environment. You will be immersed in an online environment that lets you study at your pace and your convenience while working around around your busy schedule. Click the Banner below for the Official:   : Florida Tech University Online MBA Program no GMAT USC Social Work  Online MBA Program no GMAT  with a time honored reputation for educational excellence, the research funding and  diversity, the University of Southern California’s School of Social Work prepares its students for major leadership roles in both the public and private sectors and organizations that serve our nation, its families and our communities in need. A true pioneer in the state of the art programs of our online study, the Southern California’s School of Social Work is one of the highest ranked schools of social work in Southern California and is among the top 10 in the country. The USC online  Virtual Academia Center is state of the art and offers its students the opportunity to learn and earn a Master of Social Work degree with no relocating and is specially designed to guide social workers with the extensive knowledge and hands on skills to make a real difference in our  country  while improving the lives of our population. Click the Banner below for the Official: USC School of Social Work Online MBA Program no GMAT Vermont Law School  Online MBA Program no GMAT  is truly committed to making a very significant impact in the community and the world. Our primary goal is to groom graduates who steward our normal systems and work at the intersection of the law, economics,  politics, science, and ethics. From our students, faculty, and staff the character of this university is engaged and collaborative while at the same time motivated yet ethical, sophisticated,  intelligent and caring. As a Vermont law student you will experience a high-tech, online educational environment, interacting with and learning from our expert faculty hand picked from the world’s leading environmental teachers, legal scholars, and practitioners. Throughout your rigorous curriculum, you will find yourself focused on understanding the many complexities of   true environmental law policymaking, and the legalities that guide our ever expanding environmental advocacy. Vermont Law School’s law program has always been at the very forefront of the field since the late 1970s and has also been  ranked number one by  U.S. News numerous  times since the early 199os. It still holds the distinction of being the only program available on line and is still offered from the top environmental law schools in the United Sates. We believe that our environment is the most precious resource we have. In  todays  day an age when our world is under tremendous strain, there is an ever emerging need for passionate people who can devote their careers to protecting mother earth. Our beautiful planet needs true champions who can transform laws and policy across the globe; people who will stand up and fight the influence of change through the advocacy, policy transformation and of most of all action. Vermont Law School has  two online degree options  that will give you with the expertise you need to address the ever increasingly complex nature of the environmental issues we face on an ongoing basis as a society. Click the Banner below for the Official: Vermont Law School Online MBA Program no GMAT University of San Francisco  Online MBA Program no GMAT  was founded way back in 1855, the University of San Francisco has had a longstanding tradition of true academic excellence. The University of San Francisco is accredited and was unconditionally affirmed for the maximum 7 years during its most recent university review. University of San Francisco was first accredited in 1950 so our long stand commitment to academic excellence speaks for itself. The University of San Francisco School of Business and Management is also accredited by the Association to Advance Collegiate Schools of Business) the leading accrediting body for business schools in the USA.  The University of San Francisco offers online and in demand programs that enable you to gain many new valuable skills and credentials all online, at your convenience so you can still meet your obligations to work and family. You will also  enhance your expertise with the most effective business management tools and techniques available. Whether you need to implement and process many improvements or gradually evolve your organization into a process based institution, the University of San Francisco’s Master Certificate in Business Process Management gives you the tools you need to succeed. Every online course gives you the tools you need to tap into the knowledge and experience of our leading business management experts in the nation. In as little as eight weeks, you will gain critical skills that you can apply immediately in the real world, on the job and a valuable credentials that will serve as a significant milestone as you complete each of our courses. Click the Banner below for the Official:   University of San Francisco Online MBA Program no GMAT Stay tuned for our next list of the top non GMAT programs in the country as well as some of the best or most affordable places to get your GMAT if thats the direction you want to head.

'The global financial crisis (2007-2009) is an evidence of the Essay

'The global financial crisis (2007-2009) is an evidence of the weaknesses of the existing international and national regulator - Essay Example The excessive spending and the systemic risk associated due to the fluctuation of macroeconomic factors in the world economic environment exposed the investments and the subsequent lending by the financial institutions to high risks which was slowly growing into a large bubble1. Before the global financial crisis that started in US during 2007 and rippled throughout the world, the prices of the real estate was soaring very high. Thus, people could make huge profits in the short run by investing in US properties which was unmatched with any other investment in the US and the international markets. Apart from this, the national government in US also adopted the policy of property holding right for the US citizens that encouraged the financial institutions and their intermediaries to lend for the purpose of purchase of property2. However, due to the lack of tight regulatory framework, there were cases of lending and investments that could be identified as risky due to several factors li ke repayment capability of the investor, feasibility of the investment returns, regulatory compliance, etc3. The heavy bubble of bad lending by the financial institutions burst into a global financial crisis which was an evidence of the weakness of the national and international regulatory frameworks that were put in place for avoiding the systemic risk and the excessive risk taking of the financial institutions. Systemic risk The systematic risk is explained by the risk that arises due to the fluctuation of the macro economic factors like export-import, appreciation of depreciation of currencies, economic performance of developed countries, changes in international investments, fluctuations in the financial return and risk, etc. The global financial crisis brought out the systemic risk that started in the US and melted down globally to international economies across the world4. The inter-linkage between the houses of production, markets and the financial intermediaries led the plat form where the manufacturing and the production units suffered a slowdown in the production level due to the loss of the financial intermediaries which in turn was affected due to the default risk of the borrowers who invested in the US real estate and properties5. The lack of tighter regulatory framework fuelled the investments in the US real estates. The regulatory framework for the financial institutions is also liable of not putting checks when the financial institutions relaxed their approaches on due diligence and compliance checks to find the default risk in case of lending6. The business houses were also granted loans for increasing the supply to match the rising demand. The systemic risk exposed the weakness of the regulatory frameworks when the household and the businesses defaulted in paying back the borrowed money to the financial institution and there was financial catastrophe in the US economy7. Excessive risk taking by financial institutions The global financial crisi s in 2007 to 2009 could be attributed to excessive risk taken by the financial

North American Music Essay Example | Topics and Well Written Essays - 250 words

North American Music - Essay Example North Americans believed that objects of extraordinary value possessed a spirit element, and more so sacred were regalia and obsidian blades. Getting wealth and maintaining the status that came with it were central to North Americans thoughts and consciousness. The rich men did not labor but spent most of the time in their homes making ceremonial costumes and arrows which they sold at a high cost. Feasts, ceremonies, and dances could not be held without the inclusion the ceremonial regalia that are owned by the rich. It was a hard and tedious job assembling the many scalps and skins that some pieces needed, but the effect was striking. In public ceremonies they were dazzling; they were prized for their uniqueness and beauty and the wealth they symbolized (Randel, D. M. 2003 pg. 41). Equally rare and costly were the big, oblong blades. The larger blades were more expensive. The more perfect and regular the shape of the blade the more its value; artisans deliberately and carefully chip ped them in an oblong form. From the high costs associated with the costumes, arrows, and blades that are the symbols of the ceremonial and social songs, I think that this basically means that these songs are basically preserved for the rich who mainly posses them or can easily afford them in their functions.

Analyzing Psychological Disorders Essay Example for Free

Analyzing Psychological Disorders Essay A psychiatric or psychological disorder is a disorder of psychological function severe enough to warrant treatment by a psychiatrist or clinical psychologist. Schizophrenia, emotional disorders, Anxiety and Tourette’s syndrome are all classified as psychiatric disorders. The distinguishing line between neuropsychological disorders and psychiatric disorders is quite thin. Though the two types of disorders are a result of a dysfunctional brain, the malfunctions which create psychiatric disorders remain undefined. Psychiatric disorders are often linked to environmental factors as well as dysfunction of the brain. As psychological research advances, treatments and a better understanding of psychiatric disorders comes to bear. The term schizophrenia means a psychic break or â€Å"splitting of psychic function†. (Pinel, 2007). The NIH National Library of Medicine web site defines schizophrenia as having five different categories: catatonic, disorganized, paranoid, residual, and undifferentiated. (NIH National Library of Medicine, 2008). Each category of the disorder has a specific set of symptoms that is mostly unique to that category of the disorder, but schizophrenia in general creates a delusional picture of reality which disrupts the person’s behavior, logic and emotions. A good example of schizophrenia and the related dissociative disorders are the movie Sybil or the more recent film A Beautiful Mind, and another fine example is the television show United States of Tara. Both movies and the Showtime network’s series depict the lives of a person suffering with schizophrenia or dissociative disorders. Neuroleptics and antipsychotic drugs are known to alleviate symptoms associated with schizophrenia. Clozapine is a type of neuroleptic that does not produce side effects like those associated with Parkinsons disease. The medication is known to cause blood disorders. Neuroleptic medication is used to block the dopamine receptors though it takes time for the drug to lessen schizophrenic symptoms. Though neuroleptics help schizophrenics, only certain patients do benefit from the relief these drugs can offer. Schizophrenic patients suffering from hallucinations and incoherence react to the medication; however; schizophrenics suffering from cognitive defects are not affected. The NIH National Library of Medicine web site mentioned atypical antipsychotics have proven to treat symptoms for schizophrenia  with few side effects and is the best option for those suffering with schizophrenia. (NIH National Library of Medicine, 2008). A surgeon in the 1950’s and early 1960’s used a drug called chlorpromazine on patients to alleviate swelling prior to surgery. The doctor noticed that the medicine acted as a calming agent and recommended chlorpromazine to relax hard to control psychotic patients. Chlorpromazine did not assuage the symptoms of psychosis, but the medicine showed potential for easing some symptoms in schizophrenic patients. During the research process the side effects of chlorpromazine which are symptoms of Parkinsons disease were evident. Researchers concluded that people suffering from Parkinsons disease die from a minute level of dopamine. Schizophrenics display a high-level of dopamine. Therefore Parkinsons and Schizophrenia seem to be on the opposite end of the spectrum. A breakthrough emerged in the dopamine theory with Carlsson and Lindqvist. The duo studied the Chlorpromazine in relation to schizophrenia and revised the dopamine theory of schizophrenia. Chlorpromazine was found to block dopamine receptors instead of the original theory of reducing dopamine levels. Therefore, the duo concluded through research that schizophrenia was  not due to high-levels of dopamine, but with over activity at the dopamine receptors. (Pinel, 2007). Emotional disorders are another form of a psychiatric disorder. Emotional disorders include: bipolar disorder, depression, and mania. Depression is classified as a state of unbearable sadness. At some point in a persons life one will encounter a period of depression due to a tragedy such as loss of a loved one, poor health, or a series of bad luck. However, most people will break through the grip of depression and return to a normal life. Those with depression have a hard time seeing anything in a positive light. Depression ruins relationships at work and in the home; the disease also takes over the person making it difficult to engage in a normal day-to-day routine. Mania is the opposite of depression and is linked to high energy and impulse. A person suffering from mania appears to be full of energy or â€Å"hopped up† on energy drinks like Red-Bull and caffeine; they are filled with such enthusiasm, have boundless energy and talk fast. Though it sounds like an exceptional  thing to be constantly in a good spirits there is a negative side to the disorder. Impulsiveness is a part of mania and many suffers act on impulse not thinking before they do anything. The end result is unfinished projects, bills that cannot be paid, and relationships ruined. A person who suffers from manic episodes and depression episodes is diagnosed with bipolar disorder. There are two theories created to explain the causes of emotional disorders. According to Pinel (2007), The monoamine theory of depression holds that depression is associated with under-activity at serotonergic and noradrenergic synapses. It is based on the fact that monoamine oxidase inhibitors, tricyclic antidepressants, selective serotonin-reuptake inhibitors, and selective norepinephrinereuptake inhibitors are all agonists  of serotonin, norepinephrine, or both. The second theory is Diathesis-Stress model. The second theory focuses on genetic predispositions of a person as well as environmental factors that influence the disorder. This means that people who have stress early on will overreact to stressful situations later in life in turn causing depression. (Pinel, 2007). There are four types of medicine used to treat emotional disorders. Iproniazid is a Monoamine Oxidase Inhibitor (MAOI) initially used to treat tuberculosis but failed. On the contrary the patients did not have as many depressive thoughts about the illness. Iproniazid has severe effects when combined with tyramine rich foods. Imipamine is a tricyclic antidepressant which has proven to be more effective than MAOI’s. The next medication is Lithium which was shown to alleviate symptoms of mania. The discovery was made when a researcher tested guinea pigs and the results proved to calm them. Lithium is used as a mood stabilizer in bi-polar patients since it blocks the patient from transitioning between extreme highs and lows. The fourth medicine used more commonly in recent years is selective serotonin-reuptake inhibitors (SSRIs). The most common of the SSRI’s are Prozac, Zoloft and Paxil. The SSRI’s are reported to have few side effects and are able to treat multiple disorders. (Pinel, 2007). Anxiety is chronic fear that persists in the absence of any direct threat. (Pinel, 2007). Anxiety is accompanied by rapid heartbeat, heavy or difficulty breathing and high blood pressure. There are five  types of anxiety disorders including: general anxiety, phobias, obsessive compulsiveness, panic, and post traumatic stress disorder. Theories involving anxiety disorders presume the amygdala has a role in anxiety disorders. The brain’s involvement in anxiety is cloudy at best since each patient tested shows different results. (Pinel, 2007). Benzodiazepines and serotonin agonists are the most effective medications used to combat anxiety. Valium and Librium are two of the most commonly prescribed medications, though they tend to make the patient drowsy. The medicine is  also known to be highly addictive and is recommended only for short-term usage. Buspirone is a serotonin agonist which relaxes the body and causes sleepiness. (Pinel, 2007). Tourette’s syndrome is known for involuntary movements or sounds known as tics. The Cedars-Sinai web site notes that the tics can vary from body movements and vocal tics. The tics can be a little as involuntary eye blinking or more noticeable yelling of obscene words or phrases. Little is known as to the cause of Tourette’s, however there is speculation that the limbic cortex, association cortex and thalamus are connected to the disorder. (Pinel, 2007). With the cause still a mystery there is no cure for Tourette’s, but though counseling, relaxation therapy and hypnosis healthcare professionals can help treat the disorder. (Cedars-Sinai. 2008). Psychiatric disorders vary in many ways. Schizophrenia affects the brain and causes hallucinations, emotional disorders affect a persons mood in extreme ways, and anxiety causes fear and health issues, while Tourette’s causes tics ranging from subtle to severe. Over time psychological advances in research and treatment have been made allowing professionals in the field to effectively treat each disorder. References CEDARS-SINAI. (2008). Tourettes syndrome. Retrieved June 10, 2009, from http://www.csmc.edu/5540.html NIH National Library of Medicine. (2008). Medical Encyclopedia: Schizophrenia. Retrieved June 9, 2009, from http://www.nlm.nih.gov/medlineplus/ency/article/000928.htm Pinel, J. P. J. (2007). Basics of Biopsychology. Boston, MA. Allyn and Bacon.

Tibetan Medicine Essay -- Tibet Treatment History Illness Papers

Tibetan Medicine Tibetan medicine, developed over the course of over one thousand years in the isolated mountainous terrain of Tibet and preserved despite China’s decimation of Tibetan customs, views healing in a much different way than Western physicians. Tibetan medicine emphasizes science, faith, perception, spirituality, karma, and philosophy, whereas Western medicine is based almost entirely on science. In the West, religion and spirituality are believed to have absolutely nothing to do with healing and medical practice. Without looking at Tibetan medicine in depth, the Westerner could easily dismiss Tibetan medicine as superstitious and unscientific; however, Tibetan Medicine is often very successful at treating illness, and Tibetan physicians can often cure the root of the problem, rather than merely performing a quick fix to a localized part of the body as in the West. Tibetan doctors do not recommend simply popping a pill. Instead, they see illness as a manifestation of the body†™s imbalance and seek to correct this imbalance. In order to cure a disease, behavior, lifestyle, and one’s individual ‘humoral constitution’ (the three humors and the way in which they function in the body will be fully explained later) are all very important. In order to gain a fuller understanding of the Tibetan approach, as well as appreciate why it has remained so unknown to Westerners despite its lengthy existence, one must consider the Tibetan and Western medical traditions simultaneously. One is also inclined to consider if aspects or methods of diagnoses from the Tibetan tradition could be incorporated into Western medicine since each form of practice has own benefits – Western medicine has highly sophisticated technology and the... ...he Source, 131. [8] John Avedon, In Exile from the Land of Snows, 156. [9] Vaidya Dash, Tibetan Medicine, 86. [10] Vaidya Dash, Tibetan Medicine, 87. [11] Vaidya Dash, Tibetan Medicine, 89. [12] Dr. Yeshi Dhonden. Health Through Balance. (Ithaca, NY: Snow Lion Publications, 1986), 142. [13] Dr. Dhoden, Health Through Balance, 148. [14] Dr. Dhonden, Healing from the Source, 129. [15] Christopher Hansard, The Tibetan Art of Living, (New York: Atria Books, 2001), 191. [16] Christopher Hansard, The Tibetan Art of Living, 193. [17] Christopher Hansard, The Tibetan Art of Living, 193. [18] Dr. Dhonden, Health Through Balance, 185. [19] Dr. Dhonden, Health Through Balance, 216. [20] Dr. Dhonden, Healing from the Source, 187. [21] Dr. Dhonden, Healing from the Source, 187. [22] John Avedon, In Exile from the Land of Snows, 155.

Pfizer Strageic Plan

OUTLINE FOR THE STRATEGIC PLAN Please bullet your responses. Staple the completed assignment; do not spend any money binding the assignment. Make sure to respond to every item. I. GETTING STARTED A. Steps in Strategic Management Process Step 1 |Identify the organization’s mission, vision, and value statement | |Step 2 |Determine the firms main business and organizational objectives | |Step 3 |Conduct a SWOT analysis identifying the company’s strengths, weaknesses, opportunities, and threats | |Step 4 |Construct a Competitive Profile Matrix (CPM) | |Step 5 |Construct an External Factor Evaluation (EFE) Matrix | |Step 6 |Construct and Internal Factor Evaluation (IFE) Matrix | |Step 7 |Construct a Value Chain Analysis | |Step 8 |Prepare a SPACE, BCG, TOWS Analysis, and QSPM Matrix | |Step 9 |Use the data above to weigh alternative strategies, make strategic recommendations, develop a plan of action | | |(implementation), and convey the ROI | |Step 10 |Construct Conting ency Plan | B. Information and/or materials used to complete assignment †¢ Resources used in completing the assignment are as follows: Strategic Management Concepts and Cases’ 12th edition textbook, S&P 500 website, Yahoo Finance, Bloomberg. com, Pfizer. com, Google Finance, Reuters. om, and Google search engine including the web pages cited on the Works Cited page. C. Time Frame †¢ My goal is to actively work on a portion of the outline everyday and have it completed to its entirety by the time it is due; therefore I will not have to rush to get it done last minute. D. Resources Needed – all resource your team used to complete this assignment †¢ FAMU database, online articles, company website. II. MANDATES (â€Å"MUSTS†) -CLARIFYING/UNDERSTANDING A. History/Evolution of the Organization †¢ Pfizer was founded in 1849 by Charles Pfizer and Charles Erhart in Brooklyn, New York and has remained dedicated to improving the health and well being o f individuals around the world.The demand for Pfizer’s products soared throughout the Civil War as the demand for painkillers, disinfectants and preservatives increased. In 2000, Pfizer and Warner-Lambert merge to form the new Pfizer, which created the world’s fastest growing Pharmaceutical company. In 2008, Jeff Kindler, Chairman and CEO of Pfizer, announces the next step in the company's evolution and outlines the company's plan to establish smaller operating units designed to enhance innovation and accountability, while drawing upon the advantages of Pfizer's scale and resources. On October 15, 2009, Pfizer acquires Wyeth, creating a company with a broad range of products and therapies that touch the lives of patients and consumers every day and at every stage of life.In 2010, Pfizer announces a diversified R platform named Pfizer Worldwide Research and Development, supporting excellence in small molecules, large molecules and vaccine research and development. As ap art of the acquisition of Wyeth in 2009, Pfizer initially implemented a two-division structure for research and development (BioTherapeutics and PharmaTherapeutics) to ensure the progress and steady integration of both legacy organizations. Due to the speed and effectiveness of that integration, Pfizer progresses to this new model while maintaining the same breadth and research programs. On December 1 and 2 2011 Pfizer completed the acquisitions of Excaliard Pharmaceuticals and Ferrosan Consumer Health’s Business, respectively. B.Identify formal aspects of the organization †¢ Corporate Governance Include: Board of Directors, Board Committees, Code of Ethics, CEO/CFO Certifications, Executive Officers, Policy and Procedures for Accounting and Legal Complaints †¢ Pfizer has created two distinct research organizations. The PharmaTherapeutics Research & Development Group focuses on the discovery of small molecules and related modalities; and The BioTherapeutics Research & Development Group focuses on large-molecule research, including vaccines. The goal with Pfizer doing this is to maximize opportunities within the Biomedical research sector. †¢ Pfizer has also developed an enhanced commercial operating structure.Pfizer has nine diverse health care businesses: Primary Care, Specialty Care, Oncology, Emerging Markets, Established Products, Consumer Healthcare, Nutrition, Animal Health and Capsugel. Each of these businesses is led by an executive with clear accountability for results – from product development following proof of concept to providing access to patients and through to the end of the product's life cycle. B. Identify informal aspects & culture of the organization †¢ Pfizer is sustained on innovation, which seeks a nourishing environment in which ideas and perspectives can flourish. It is an array of unique characteristics, perspectives, and life experiences. Pfizer Colleague Resource Groups (CRGs) are organized by coll eagues who join together to provide a positive forum for professional development. By embracing diversity of thought and experience, our CRGs help drive innovation and build on our success. †¢ David Simmons, the president and general manager of the Established Products Business Unit at Pfizer. Simmons has been highly successful at building a new, non-traditional culture within Pfizer for his business unit. One example of this was that Simmons was able to product high quality drugs at affordable costs, and he did this as high grossing patents were near expiration III. VISION STATEMENT, MISSION STATEMENT & VALUES STATEMENT ANALYSES A. Vision StatementAt Pfizer, we're inspired by a single goal: your health. That's why we're dedicated to developing new, safe medicines to prevent and treat the world's most serious diseases. And why we are making them available to the people who need them most. We believe that from progress comes hope and the promise of a healthier world. B. Vision S tatement Analysis – Does it answer the question â€Å"What to do we want to become? † If not, revise it. If organization does not have one, create one. †¢ Yes, I believe that it answers the question as to what they want to become. Its states that they are dedicated to developing new ways to prevent and treat diseases. C. Values Statement Pfizer does not have a value statement. D. Value Statement Analysis – Does it represent the organization’s guiding principles? If not, revise it. If organization does not have one, create one. †¢ Pfizer will work to provide the best quality drugs that will cater to the most people. We will ensure that as a company we will work to do what is best for our patients, physicians and consumers. B. Mission Statement †¢ We will become the world's most valued company to patients, customers, colleagues, investors, business partners, and the communities where we work and live. D. Mission Statement Analysis – Do es it have the 9 components? If not, revise it to include all 9 components.If organization does not have one, create one. †¢ No, the mission statement does not include all the nine components. After revising the mission statement, it should be read: o We will become the world’s most valued company to patients, customers, colleagues, investors, business partners, and the communities where we work and live. We will ensure that we provide products of the best quality at affordable prices to all. We will work hard to ensure that we keep up with the needs and problems of our consumers and provide what is best. We will continue to promote the well-being of our consumers as well as the well-being of our shareholders and employees as well as promote diversity.We will keep abreast of the ever-changing technology to ensure that they needs of our consumers are met at all times and also that we will not become obsolete to our customers. We will forever be dedicated to developing new , safe medicines to prevent and treat the world's most serious diseases. And why we are making them available to the people who need them most. |List each of the 9 components |Excerpts from Mission Statement addressing the component | |1. Customers |We will work hard to ensure that we keep up with the needs and problems of our consumers and provide what is| | |best. | |2.Products or Services |We will ensure that we provide products of the best quality at affordable prices to all. | |3. Markets |We will ensure that we provide products of the best quality at affordable prices to all. | |4. Technology |We will keep abreast of the ever-changing technology to ensure that they needs of our consumers are met at | | |all times and also that we will not become obsolete to our customers. | |5. Concern for survival, growth, and profitability|We will keep abreast of the ever-changing technology to ensure that they needs of our consumers re met at | | |all times and also that we will not become obsolete to our customers. | |6. Philosophy |We will forever be dedicated to developing new, safe medicines to prevent and treat the world's most serious| | |diseases. And why we are making them available to the people who need them most. | |7. Self- Concept |We will become the world’s most valued company to patients, customers, colleagues, investors, business | | |partners, and the communities where we work and live. | |8.Concern for public image |We will continue to promote the well-being of our consumers as well as the well-being of our shareholders | | |and employees as well as promote diversity. | |9. Concern for employees |We will become the world’s most valued company to patients, customers, colleagues, investors, business | | |partners, and the communities where we work and live. | IV. ASSESSING EXTERNAL ENVIRONMENT A. Identify Opportunities / Threats – Analyze trends in the following areas: political, legal, competitive, economic, social, cultural, demo graphic, technological, environmental, and governmental. Provide at least 1 opportunity & 1 threat for each of the 10 areas. Provide responses in bullet format. Political | |Opportunity |Threat | |Measures taken to close the Coverage gap also known as the donut hole may |New Health care Reform Bill was put in place 2010. This law requires drug | |result in people using more brand name drugs rather than buying generic. 9 |producers to make rebates to state Medicaid agencies based on their costs to | | |provide prescription drugs to Medicaid beneficiaries. | | |Constant pressure to lower prescription drug prices from the government2 | |Legal | |Opportunity |Threat | |Acquisitions and in-licensing /co-development opportunities such as recent |Expiration of Patents for drugs, face a loss of up to billions of dollars due | |acquisitions of Excaliard and Ferrosan Consumer Health’s Business in December |to generics taking market share.For example, Lipitor, which grossed 11 bil lion| |2011 may help Pfizer meet unmet needs of their customers. 23 |in revenues last year expired November 28, 2011. This means that other | | |companies are allowed to produce the generic version of the drug. 2 | | |Number of New Molecular Entities approved by the FDA has declined. In 2009, | | |NMEs approved were 26 and 2010 were 21. 2 | | |Beginning of 2011 was a series of new fees in the form of excise taxes payable | | |to the federal government. 12 | |Competitive | |Opportunity |Threat | |Barriers for additional companies to enter the market are high. 4 |French drug maker Sanofi-Aventis’ $20 billion acquisition of Genzyme Corp. | | |completed in April 2011 | | |Fierce competition among Pharmaceutical companies such as Proctor & Gamble and | | |Johnson & Johnson. | | |Japanese drug sales are also expected to expand with current sales of 60 | | |billion, 11% of the world market share. | |Economic | |Opportunity |Threat | |Demands for certain drugs are relatively in elastic. 4 |Based on the projected losses due to loss of market share, Pfizer has shed | | |53,000 and 61, 000 jobs in 2010 and 2009 respectively | | |The decline in spending in the US in the last few years | | |Revenue may be hurt by ongoing negative effects from U. S. ealth care reform | | |and austerity pricing in Europe | | |Inflation will cause an increase in cost and raise drug prices | | |Competition from newer, better drugs may be a threat to sales. For example, | | |Vivus is a new ED drug that may be able to compete with Viagra. 3 | |Social | |Opportunity |Threat | |450 million Americans are over the age of 65 and healthcare spending is the |Number of NMEs approved by the FDA has declined12 | |highest among these individuals2 | | |Humana and Pfizer Form Research Partnership to Improve Health Care Delivery for| | |Seniors in 2011. | | |Cultural | |Opportunity |Threat | |Like GlaxoSmithKline and Abbott Labs in particular — Pfizer has its sights on |Number of legis lative proposals seeking to allow importation of medicines into | |developing countries for a revenue bump. 13 |the U. S. and revenues could be affected | |Demographic | |Opportunity |Threat | |Asian drug sales are also expected to expand.For example, Takeda |77 million people by 2031 will be enrolled in Medicare and Health care and | |Pharmaceutical Company, Asia's biggest drug maker, reported an 18 percent jump |Medicare will not be able to finance this many people2 | |in first-quarter profit, helped by the sale of new medicines in the beginning | | |of 2011. 9 | | |Technological | |Opportunity |Threat | |Pfizer has plenty of drugs in its pipeline with blockbuster potential. 3 | | |Environmental | |Opportunity |Threat | |Adoption of new environmental strategies to be more socially responsible |Adverse effect on drug prices due to threat of imported drugs and threat of | | |counterfeited drugs due to importing and exporting. | B. Monitor Major Stakeholders/Stakeholder Analys is – Customers, Competitors (list at least 3 of the organizations major competitors, Individuals in the community, Employees, Stockholders, etc. 1. Identify Stakeholders |Identify Internal Stakeholders |Identify External Stakeholders | |Ian C.Reed- President, CEO, Director |Johnson & Johnson | |Frank A. D’Amelio- CFO, EVP of Business Ops. |JP Morgan Chase & Co | |Mikael Dolsten- Pfizer Worldwide R&D |Northern Trust | |Freda- Lewis Hall- EVP, Chief Medical Officer |Proctor & Gamble | 2. Stakeholder Matrix – classify the internal & external stakeholders identified above into the appropriate boxes. High Interest/Importance, High Influence |High Interest/Importance, Low Influence | |Ian Reed |Proctor & Gamble | |Frank D’Amelio |Johnson & Johnson | |JP Morgan Chase & Co |Dow Chemical | |State Street Corporation |Merck and Co Inc. | | |Customers | | Employees | |Low Interest/Importance, High Influence |Low Interest/Importance, Low Influence | |Governme nt |Lenders | |Insurance Companies |Suppliers | | | | | | | | | | 3. Stakeholder Analysis |Stakeholder |Responsibility of |What does organization |Stakeholder’s potential |Stakeholders’ perceived |Stakeholder Management | | |Stakeholder to the |expect the stakeholder to |impact on the organization |attitudes and/or risks to |Strategy (SMS) | | |organization |provide? (high, medium, or low) |the organization | | | | | | | |N/A | |Investors |Fund the organization |Provide funding and |High |High Risk; Conservative | | | | |liquidity to the | |Attitude | | | | |organization | | | | | |Strategic plans and |Provide expertise, | |High Risk; Positive |Bottom-Up | |Employees |operations.Supports the|knowledge and value |High |Attitude | | | |functionality and | | | | | | |operational processes | | | | | | |Make critical decisions |Provide conceptual |High |High risk; Conservative |Top-down | |Shareholders | |knowledge and top-down flow| |Attitude | | | | |of decision maki ng | | | | | |Meet market demands |Provide products and | |Medium Risk; Positive |N/A | |Suppliers | |services |Medium |Attitude | | External Factor Evaluation |Opportunities | | | | | |Weight |Rating (1-4) |Weighted Score | |1. Measures taken to close the donut hole may result in people using more brand |. 07 |3 |. 1 | |name drugs rather than buying generic | | | | |2. Acquisitions and in-licensing /co-development opportunities |. 06 |4 |. 24 | |3. 450 million Americans are over the age of 65 and healthcare spending is the |. 07 |4 |. 28 | |highest among these individuals | | | | |4. Expansion of the biologic pharmacy market. |. 07 |4 |. 28 | |5. Bought King pharmaceutical for $3. 6 billion which would open up more |. 06 |4 |. 4 | |manufacture and sales adding to the capital of the company (Carrie, 2009). | | | | |6. Barriers for additional companies to enter into market are high |. 05 |4 |. 20 | |7. Demands for certain drugs are relatively inelastic. |. 07 |4 |. 28 | |Threats | | | | |8. Japanese drug sales are also expected to expand with current sales of 60 |. 08 |2 |. 6 | |billion, 11% of the world market share. | | | | |9. In 2009, Pfizer got assessed a 2. 3 billion fine for which they employed illegal|. 08 |1 |. 08 | |marketing strategies. | | | | |10. Large manufacture and low research for new inductions in the market could |. 07 |2 |. 14 | |decline the profitability. | | | | |11. Constant pressure to lower prescription drug prices from the government |. 5 |2 |. 1 | |12. Number of NMEs approved by the FDA has declined |. 04 |2 |. 08 | |13. The decline in spending in the US in the last few years |. 07 |1 |. 07 | |14. Inflation will cause an increase in cost and raise drug prices |. 06 |1 |. 06 | |15. Number of legislative proposals seeking to allow importation of medicines into|. 05 |2 |. 1 | |the U. S. nd revenues could be affected | | | | |16. 77 million people by 2031 will be enrolled in Medicare and Health care and |. 06 |2 |. 12 | |Medicare will not be able to finance this many people | | | | | | |Total |2. 64 | Pfizer seems to be taking advantage of the opportunities presented as well as avoiding threats but there is still room for improvement.For example, Pfizer seems to be taking advantage of some of the acquisitions that they have had over the last two years. They are seizing the opportunities of the expanding biological pharmacy market. Starting with the acquisition of Wyeth in 2009 and then the acquisitions of Excaliard and Ferrosan Consumer Health’s Business. Pfizer saw that they were not meeting the needs of some of their customers but their competitors were. Excaliard is a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring. Ferrosan Consumer Health’s Business focuses on dietary supplements and lifestyle products.In addition to this, although New Molecular Entities approved by the FDA have declined, Pfizer has managed to get 3 drugs approved by the FDA in 2011 alone. Lastly, Pfizer has responded relatively well to the governmental pressure of lowering their prices as well as the Lipitor patent expiring at the end of November. Pfizer has implemented multiple rebate and discount programs to help assist their consumers. For example, Pfizer has recently partnered with Wal-Mart to offer a $4 prescription program allowing consumers to obtain their prescriptions at that low price. This helps to mitigate the complete loss of revenue and market share if consumers were to go to generic all together.I believe that the reason Pfizer did not receive a score of higher than a 3 was because a lot of these new policies have been recent (2010, 2011) and Pfizer seems to be trying to figure out how to remain profitable as well as cater to their consumers and these acquisitions are all relatively new and Pfizer seems to be just getting adjusted. Competitive Profile Matrix | |Pfizer |Johnson & Joh nson |Eli Lilly | |Critical Success Factors |Weight |Rating |Weighted Score |Rating |Weighted |Rating |Weighted Score | | | | | | |Score | | | |Organizational Structure |. 05 |2 |. 10 |4 |. 20 |1 |. 5 | |Price Competitiveness |. 10 |3 |. 30 |3 |. 30 |3 |. 30 | |Advertising |. 04 |1 |. 04 |1 |. 04 |4 |. 16 | |Product Quality |. 10 |3 |. 30 |3 |. 30 |3 |. 30 | |Sales Distribution |. 10 |4 |. 40 |3 |. 30 |2 |. 0 | |Customer Loyalty |. 03 |3 |. 09 |3 |. 09 |3 |. 09 | |Global Expansion |. 11 |4 |. 44 |3 |. 33 |2 |. 22 | |Market Share |. 11 |4 |. 44 |4 |. 44 |3 |. 33 | |Demographics |. 03 |3 |. 09 |3 |. 09 |3 |. 9 | |Financial Position |. 15 |4 |. 60 |3 |. 45 |2 |. 30 | |Research and Development |. 13 |4 |. 52 |4 |. 52 |3 |. 39 | |Innovation |. 10 |3 |. 30 |3 |. 30 |2 |. 20 | |Total |1. 00 | |3. 52 | |3. 16 | |2. 58 |From constructing the Competitive Profile Matrix, it is apparent that Pfizer is the strongest among the three competitors compared. V. ASSESSING INTERNAL ENVIRONMENT A. Stren gths/Weaknesses |Management | |Strength |Weakness | |In June 2011, Pfizer announced strategic partnerships with ICON plc and PAREXEL|Sometimes Pfizer may have to discontinue the production of drugs; therefore the| |International Corporation, both of which will serve as strategic providers of |demand for that drug increases. |clinical trial implementation services over a five-year period beginning in | | |June 2011 | | |Adoption of new environmental strategies to be more socially responsible | | |Working with numerous companies to do collaborative work in research and | | |development. | | |Pfizer is continually developing new strategies such as plant restructuring and| | |energy master plan. | |Pfizer is divided into multiple sectors so that most leaders have a specific | | |rather than general role. | | |Pfizer expects to increase its market share from 4% to 6% by reinforcing its | | |leadership, expanding developments in high growth markets, building leadership | | |in oncology and taking advantage of R&D in Asia and other countries. | |Marketing | |Strength |Weakness | |Renewed emphasis in the faster growing fields of specialty pharmaceuticals, |Co marketing with other pharmaceutical companies may slow down its global | |biologics, vaccines, and, in some cases, even generics. |growth. | |Its number one pharmaceutical from sales point of view and its marketing |Decreased amount of advertising | |infrastructure is well established throughout the world. | | |Pfizer as six markets, which include Brazil, China, Mexico, Turkey, Russia, and| | |India. | |For the ninth consecutive year, the Pfizer Pharmaceutical Sales Force was voted| | |as first overall in Verispan's â€Å"Pharmaceutical Sales Force Structures. | | |Human Resources | |Strength |Weakness | |Global working network with 95,000 workers |According the glassdoor. om, the company morale is at an all time low | |Accounting/Financials | |Strength |Weakness | |7. 5% ranking corporation market share | Prices, according to the federal government, are too high and are currently | |Sales have increased from 16. 02% in 2008 to 22. 89% in 2010. |trying to get Pfizer to cut their prices. | |High budget pharmaceutical industries having the revenue of $50 billion |Lowest Earnings per Share among competitors. For example, Pfizer has an EPS of | | |$. 48 and Johnson & Johnson and Eli Lilly have an EPS of $1. 5 and $1. 11, | | |respectively. | | |The integration of large acquisitions including a pair by Pfizer — hasn’t | | |resulted in s great return on equity. | | |Each new drug can cost as much as $1 billion to develop, with no guarantee of | | |success. |Internal Technology | |Strength |Weakness | |Due to the expectation of the drugs expiring and the decline and market share, |Delays caused by regulations and the unsuccessful completion of clinical trials| |Pfizer has focused most of the R&D on Biotech based treatments |reduce the potential recovery and returns of investme nts such as R&D. | |Their research and development sector is highly established and in good | | |strength. | | |Renewed emphasis in the faster growing fields of specialty pharmaceuticals, | | |biologics, vaccines, and, in some cases, even generics. | | |Pfizer Announces Licensing Agreement With Puma Biotechnology, Inc.For The | | |Development And Commercialization Of Neratinib, An Investigational Pan-HER | | |Inhibitor | | |U. S. Food And Drug Administration Approves Pfizer’s XALKORI ® (crizotinib) As | | |First And Only Therapy Specifically For Patients With Locally Advanced Or | | |Metastatic ALK-Positive Non-Small Cell Lung Cancer. | | | | |Other | |Strength |Weakness | |Chance to acquire new patents for new technological products |Currently only serving American, European and Asian markets. They are not | |Pfizer has been public in its efforts to address climate change. Our Energy and|serving African or Australian markets. | |Climate Change Program seeks to minimize the cost and operational restrictions | | |arising from a carbon-constrained environment, reduce Pfizer's contribution to | | |GHG emissions, and assess the risk presented to Pfizer's operations from the | | |potential physical changes resulting from a warming global climate. | |Pfizer has committed to ensure that their quality is top notch and no | | |counterfeit products have been purchased by their consumers. | | |Pfizer is committed to its outsourcing. The key considerations for outsourcing | | |decisions include the ability to supply and capacity flexibility, regulatory | | |compliance and safe practices, technology and cost competiveness. | | |Pfizer has a structure for quality.Some components include creating, | | |implementing, and upholding standard operating procedures for trial execution, | | |a quality scientific and medical design of the protocol, clinical investigator | | |and site pre-assessment and selection, regulatory agency and ethics committee | | |approval, dev eloping and providing appropriate informed consent, adequate | | |recording and reporting of data, periodic monitoring and audits. | | B. Value Chain Analysis – Graphically depict the organization’s value chain |Infrastructure: | |-Pfizer's Executive Leadership Team is the company's senior-most leadership and decision-making management body. It brings together our top leaders to focus on major | |financial, strategic and operational decisions for the company. | |-The Governance structure of Pfizer consists of an Executive Board (CEO, CFO, President), Board of Directors (Dennis Ausiello, Michael S.Brown), Shareholders (JPMorgan,| |Northern Trust, Ian Reed, State Street Corporation). | |-Pfizer has made several initiatives to ensure a diverse company culture. They also have recognized their responsibility towards their customers. Certain policies | |include: Business conduct, Lobbying and Political contributions, Sales and Marketing, Research and clinical trials, workpl ace standards, and laboratory animal care. 10 | |Human Resource Management: | |Pfizer has agreements with different universities and recruit from different areas of study. This serves to create a diverse environment and fosters a challenging and | |open culture.Some of their values with regards to their employees are: sustain focus on performance, create an inclusive environment, exchange open discussion and | |debate, manage change, develop people, and align across Pfizer. 2 | |Research and Development: | |Pfizer is prioritizing its research and development efforts in areas with the greatest scientific and commercial promise: immunology and inflammation, oncology, | |cardiovascular and metabolic diseases, neuroscience and pain, and vaccines.Through major research efforts across multiple modalities including small molecules, | |biologics and vaccines. | |Pfizer has set up the phases of clinical development from making the drug to administering the drug through clinical trials and then manufacturing and selling the drugs. | |2 | |Procurement: | |Pfizer is expected to increase outsourced manufacturing of products from approximately 17 percent to 30 percent over the next three years. Key considerations for | |outsourcing decisions include the ability to supply, capacity flexibility, cost competitiveness,and technology. | |Inbound Logistics: |Operations: |Outbound Logistics: |Marketing and Sales: |Service: | |Pfizer procurement professionals |-Pfizer has nine diverse health|-Pfizer has trained over 95 |-Channels of marketing include:|-Pfizer is committed to providing a | |regularly |care businesses: Primary Care, |percent of colleagues worldwide|Television, print ad and online|quality drug to their customers. | |engage with suppliers to reinforce |Specialty Care, Oncology, |in basic problem solving, which|ads. Pfizer has created programs such as | |Pfizer’s expectations in all |Emerging Markets, Established |has resulted in over 8,000 |-Pharmaceutical sa les |the $4 Wal-Mart prescription program| |operational business areas. This |Products, Consumer Healthcare, |improvement |representatives are among the |to provide their drugs at a fraction| |collaboration leads |Nutrition, Animal Health and |projects across the world in |top in the nation. They receive|of the cost. | |to improvement projects with |Capsugel†. 8 |the last five |extensive training so they are |- | |significant performance benefits, | |years. Significant improvements|knowledgeable of the drugs. | |such as reduced | |to Pfizer’s |They have knowledge of Pfizer | | |packaging and transportation costs, | |key products have delivered a |products as well as their | | |and elimination of undesirable | |40 percent reduction in both |competitors. 2 | | |chemicals through process | |the time to make and ship the | | | |improvements†. 8 | |product as well as allowing a | | | | | |reduction in inventory†. 8 | | | Primary Activities Financial Ratios: Finan cial Ratios |Pfizer Inc |Industry |S&P 500 |How Pfizer is doing in | | | | | |comparison to the industry? | |Growth Rate % | | | | | |Sales (Qtr vs. year ago Qtr) |7. 5 |5. 90 |14. 40 |Better | |Net Income (YTD vs. YTD) NA |NA |NA | | |Net Income (Qtr vs. year ago Qtr) |185. 10 |66. 00 |46. 30 |Better | |Sales (5 Year Annual Avg) |7. 42 |7. 59 |8. 28 |Worse | |Net Income (5-Year Annual Avg) |1. 68 |2. 38 |8. 48 |Worse | |Dividends (5-Year Annual Avg) |-1. 08 |9. 81 |5. 9 |Worse | | | | | | | |Financial Condition | | | | | |Debt/Equity Ratio |. 46 |1. 14 |1. 05 |Better | |Current Ratio |2. 3 |1. 7 |1. 4 |Better | |Quick Ratio |1. 9 |1. 4 |1. 0 |Better | |Interest Coverage |9. 6 |23. 5 |316. |Worse | | | | | | | |Investment Returns % | | | | | |Return on Equity |11. 4 |30. 0 |26. 3 |Worse | |Return on Assets |5. 2 |8. 8 |8. 9 |Worse | |Return on Capital |6. 1 |11. 7 |11. 9 |Worse | | | | | | |Management Efficiency | | | | | |Income/Employee |91,763 |84,518 |130,228 |Better | |Re venue/Employee |616,998 |539,073 |1 Mil |Better | |Receivable Turnover |4. 5 |5. 5 |15. 9 |Worse | |Assets Turnover |0. 4 |0. 6 |0. |Better | |Inventory Turnover |1. 8 |2. 7 |12. 5 |Worse | * http://moneycentral. msn. com/investor/invsub/results/compare. asp? symbol=pfe* C. Assess all Functional areas using the internal checklists Management Audit Checklist – Give an example for each response |1. Does the organization use strategic management concepts? |Yes, Pfizer is continually developing new strategies such as plant restructuring and | | |energy master plan.For example, In June 2011, Pfizer announced strategic partnerships | | |with ICON plc and PAREXEL International Corporation, both of which will serve as strategic| | |providers of clinical trial implementation services over a five-year period beginning in | | |June 2011 | |2. Are organization objectives and goals measurable and well |Yes, some of Pfizer’s goals include maximizing opportunities in Biomedical res earch, | |communicated? |forging relationships with ey customers, etc. | |3. Do managers at all hierarchical levels plan effectively? |Yes, Pfizer is divided into multiple sectors so that most leaders have a specific rather | | |than general role. Pfizer is divided into 2 sectors, the PharmaTherapeutics Research & | | |Development Group and the BioTherapeutics Research & Development Group. Each sector has | | |its own managers; therefore it becomes easier to be able to plan effectively. | |4.Is the organization’s structure appropriate? |Yes, their leadership brings together top leaders to focus on major financial, operational| | |and strategic decisions. They have managers for every sector who work specifically to | | |foster the success of that sector. This creates an atmosphere for managers and employees | | |to focus on their specific sector rather than divide their attention. | |5. Are job descriptions and job specifications clear? Yes, Pfizer provides a detailed descript ion of the top managers and what they do as well | | |as what they expect from all their employees. | |6. Is employee morale high? |No, according to glassdoor. com, the employee morale is at an all time low. | |7. Is employee turnover and absenteeism low? |Yes, Pfizer currently has over 110,000 employees and they have managed to maintain their | | |staff turnover at a rate lower than 10% per year for the past 10 years, despite the | | |industry's average rate of 15%. | |8.Are organizational reward and control mechanisms effective? |Yes, Pfizer has recently raised its salary for its employees from the 50th to the 75th | | |percentile of markets rates. | Marketing Audit Checklist – Give an example for each response |1. Are markets segmented effectively? |Yes, Pfizer as six markets which include Brazil, China, Mexico, Turkey, Russia, and India | |2. Is the organization positioned well among competitors? |Yes, Pfizer ranks #2 right behind Proctor and Gamble | |3. Has the organiza tion’s market share been increasing? Yes, Pfizer expects to increase its market share from 4% to 6% by reinforcing its | | |leadership, expanding developments in high growth markets, building leadership in oncology| | |and taking advantage of R&D in Asia and other countries. | |4. Are present channels of distribution reliable and |No, according to Pfizer. com, globalization has made channels of distribution easy targets | |cost-effective? |for counterfeiting products. Drug Importation also poses a difficult task of closely | | |monitoring these drugs to prevent counterfeiting and damaged goods. | |5. Does the organization have an effective sales organization? Yes, For the ninth consecutive year, the Pfizer Pharmaceutical Sales Force was voted as | | |first overall in Verispan's â€Å"Pharmaceutical Sales Force Structures. | |6. Does the organization conduct market research? |Yes, this is the basis for their business. They have to research the causes and effects | | |for the drugs that they manufacture and produce. | |7. Are the organization’s products and services priced |No, the federal government has been trying to get Pfizer to decrease its prices to be more| |appropriately? |affordable for customers. | |8.Does the organization have an effective promotion, advertising,|Yes, Pfizer products have become a household name for most. Pfizer has a marketing | |and publicity strategy? |strength in major geographical and therapeutic areas. | |9. Is marketing planning and budgeting effective? |Yes, one of Pfizer’s plans is to cut the budget of R by 12 million dollars by the end of| | |2012. | |10. Do the organization’s marketing managers have adequate |Yes, from inspection of the top marketing managers, they all have experience prior to | |experience and training? |Pfizer. | |11.Are product quality and customer service good? |Yes, Pfizer has committed to ensure that their quality is top notch and no counterfeit | | |products have been pur chased by their consumers. They have implemented numerous plans in | | |order to assure top quality. This stems from their procurement strategies such as making | | |sure that their suppliers only produce the utmost quality of products. | Finance Audit Checklist – Give an example for each response |1.Where is the organization financially strong & weak as |Yes, the company has a high gross profit margin at 81. 5%, which indicates a strong | |indicated by financial ratio analyses? |position in the market. | |2. Can the organization raise needed short-term capital? |Yes, their operating activity ratios for the most part have improved. For example, their | | |inventory turnover decreased in 2009 to 4. 03 but then increased in 2010 to 8. 07. | |3. Can the organization raise needed long-term capital through |Yes, most of the company’s ratios seemed to have decreased in 2009, but most recuperated | |debt and/or equity? |in 2010. For xample, total asset turnover decreased in 2 009 to 0. 23 but then increased in| | |2010 to 0. 35. | |4. Does the organization have sufficient working capital? |Yes, the company’s working capital increased since 2009. In 2010, the working capital was | | |$18,991 million. | |5. Are capital budgeting procedures effective? |Yes, the company has decided to cut back in R costs in order to save capital | |6. Are dividend payout policies reasonable? |No, the payout for dividends is currently $. 20 per share which is $. 3 less than its | | |number one competitor, Proctor & Gamble | |7. Does the organization have good relations with its investors |Yes, all the financials are reported online and there is a sense of transparency with the | |and stockholders? |investors and the company. | |8. Are the organization’s financial managers experienced and well |Yes, all managers have experience prior to working at Pfizer | |trained? | | R Audit Checklist – Give an example for each response |1.Does the organization have R facilities? Are they adequate? |Yes, Pfizer has the world’s largest research. Pfizer has six main research locations, | | |which include: New York, California, Massachusetts, Connecticut, UK and Missouri. | |2. If outside R organizations are used, are they cost-effective? |N/A, Pfizer does not use outside R organizations. | |3. Are the organization’s R personnel well qualified? |Yes, Pfizer has a rigorous screening process for their scientists that work in R. This | | |is done to ensure a quality product. | |4. Are management information and computer systems adequate? Yes, Pfizer engaged PA Consulting Group to create and implement a rapid, insightful | | |information management solution that would help the company manage and derive value from | | |the wealth of project and agreement information. 14 | |5. Is communication between R and other organizational units |Yes, communication has to be effective when it comes to R and the other sectors. This | |effective? |has to be done to ensure safe, effective products. | |6. Are present products technologically competitive? |Yes, Pfizer has some of the leading medications in areas such as Internal Medicine.The | | |drug Lipitor is the leading drug for the reduction of cholesterol in the industry as of | |